Sana: UP421 survives 12 months in T1D with no immunosuppression; plans SC451 IND, SG293 data in 2026

Sana Biotechnology, Inc.

UP421, a hypoimmune pancreatic islet cell therapy, continued to survive and function at 12 months post-transplant in a T1D patient with no immunosuppression.
On track to file an IND and begin Phase 1 trial for SC451, an iPSC-derived islet cell therapy, as early as 2026.
Goal to generate initial human data in 2026 for SG293, an in vivo CD19-directed CAR T cell therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.